ALTEOGEN (196170) Q2 2025 earnings summary

Executive summary

• Achieved strong revenue growth in H1 2025, driven by major licensing deals and milestone payments, especially for ALT-B4 technology and biosimilar products.

• Maintained robust cash position and increased R&D investments to support pipeline advancement.

• Completed significant M&A activity, consolidating subsidiaries to streamline operations.

Financial highlights

• H1 2025 consolidated revenue: KRW 102.3B, up from KRW 96.5B in H1 2024.

• Operating income: KRW 63.1B, net income: KRW 48.7B, both significantly improved year-over-year.

• Cash and cash equivalents at period end: KRW 63.9B, up from KRW 19.0B at end-2024.

• R&D expenses (consolidated): KRW 23.7B, representing 23.2% of sales.

Outlook and guidance

• Expects continued revenue growth from new and existing licensing agreements, especially for ALT-B4 and biosimilar launches.

• Anticipates further milestone and royalty income as pipeline products advance to commercialization.

• Plans to expand global commercialization, particularly in the US, EU, and China.